ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced its financial results for the first quarter ended March 31, 2015.
” “AMPYRA’s 27% increase in sales this quarter over the same period last year reflects the continued strong growth of the brand, which is increasingly considered a standard of care to improve walking in people with MS,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO.
Help employers find you! Check out all the jobs and post your resume.
” “AMPYRA’s 27% increase in sales this quarter over the same period last year reflects the continued strong growth of the brand, which is increasingly considered a standard of care to improve walking in people with MS,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO.
Help employers find you! Check out all the jobs and post your resume.
